Heart Failure

In the next phase of the program, researchers will dig into the data they have gathered so far to identify the best practices for reducing 30- and 90-day readmission rates.

A recent study appearing in the American Heart Association journal Circulation, found that looking at how well hospitals adhere to treatment guidelines for heart failure is more important than comparing patient volumes at hospitals.

Higher resting heart rate (HR) and increases in HR over time are associated with increased risk of adverse cardiovascular (CV) and non-CV events, such as incident heart failure and all-cause mortality, according to a study published in JAMA Cardiology.

The annual meeting of the American College of Cardiology (ACC), which runs March 10-12, 2018, in Orlando, Florida, will open with cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent). The meeting also features updates on anti-inflammatory drugs, the use of SGLT2 inhibitors in heart failure, and how cardiology is shifting to new healthcare delivery models.

Biomarkers of renal dysfunction, endothelial dysfunction, and inflammation were associated with incident heart failure with reduced ejection fraction. By contrast, only natriuretic peptides and urinary albumin to creatinine ratio were associated with heart failure with preserved ejection fraction (HFpEF), a finding that highlights the need for future studies focused on identifying novel biomarkers of the risk of HFpEF, according to a study in JAMA Cardiology.

Reimbursement structures and population demographics change the way hospitals approach heart failure, explained Amar Bhakta, MD, of Rush University Medical Center.

An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.

A new pathway uses a multidisciplinary team to help reduce 30-day heart failure readmissions, explained Amar Bhakta, MD, of Rush University Medical Center.

The payment reform movement has changed the thinking about what can be done for patients with diabetes and heart failure, for the good of patients.

The first major update since 2003 was announced this week during the 2017 American Heart Association Scientific Sessions.

Reimbursement policy has been a driver of change in the way hospitals handle heart failure patients.

During a session at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, a cardiologist joined rheumatologists to give a detailed look at the relationship between rheumatic conditions and cardiovascular disease.

While current, prior, and change in the Kansas City Cardiomyopathy Questionnaire score were all significnatly associated with lower risk of mortality and heart failure hospitalization in isolation, when the current score was included with either prior or change score, only the current score was significantly associated with lower risk for all-cause mortality.

Transitional care interventions are considered evidence-based, designed to ensure coordination and continuity of care when patients are transferred to different levels of care, and to prevent hospital readmissions of heart failure patients.

Patients with heart failure tend to have other health issues, requiring cardiologists to understand how to care for heart failure while keeping in mind treatment for these other comorbidities, said panelists at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

The connection between diabetes and cardiovascular disease is well-known, but a new study gets at the mechanism of how this occurs.

Hospital 30-day readmission rates associated with the Affordable Care Act for heart failure, acute myocardial infarction, and pneumonia are weakly but significantly correlated with reductions in hospital 30-day mortality rates after discharge, according to a new study.

Researchers at the Medical College of Georgia show how age causes a protection against inflammation to decline.

The findings demonstrate why quality ratings focus heavily on managing diabetes and targeting 30-day readmission rates.

The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California.

At a symposium at the 77th Scientific Sessions of the American Diabetes Association, experts suggested that the relationship between heart failure and diabetes is finally getting the attention it deserves.